TY - JOUR T1 - Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States JF - medRxiv DO - 10.1101/19012435 SP - 19012435 AU - Mohsen Yaghoubi AU - Amin Adibi AU - Zafar Zafari AU - J Mark FitzGerald AU - Shawn D. Aaron AU - Kate M. Johnson AU - Mohsen Sadatsafavi Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/22/19012435.abstract N2 - Background Asthma diagnosis in the community is often made without objective testing.Objective The aim of this study was to evaluate the cost-effectiveness of implementing a stepwise objective diagnostic verification algorithm among patients with community-diagnosed asthma in the United States (US).Methods We developed a probabilistic time-in-state cohort model that compared a stepwise asthma verification algorithm based on spirometry and methacholine challenge test against the current standard of care over 20 years. Model input parameters were informed from the literature and with original data analyses when required. The target population was US adults (≥15 y/o) with physician-diagnosed asthma. The final outcomes were costs (in 2018 $) and quality-adjusted life years (QALYs), discounted at 3% annually. Deterministic and probabilistic analyses were undertaken to examine the effect of alternative assumptions and uncertainty in model parameters on the results.Results In a simulated cohort of 10,000 adults with diagnosed asthma, the stepwise algorithm resulted in the removal of diagnosis in 3,366. This was projected to be associated with savings of $36.26 million in direct costs and a gain of 4,049.28 QALYs over 20 years. Extrapolating these results to the US population indicated an undiscounted potential savings of $56.48 billion over 20 years. Results were robust against alternative assumptions and plausible changes in values of input parameters.Conclusion Implementation of a simple diagnostic testing algorithm to verify asthma diagnosis might result in substantial savings and improvement in patients’ quality of life.Key MessagesCompared with current standards of practice, the implementation of an asthma verification algorithm among US adults with diagnosed asthma can be associated with reduction in costs and gain in quality of life.There is substantial room for improving patient care and outcomes through promoting objective asthma diagnosis.Capsule summary Asthma ‘overdiagnosis’ is common among US adults. An objective, stepwise verification algorithm for re-evaluation of asthma diagnosis can result in substantial savings in costs and improvements in quality of life.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by an independent research contract by MethaPharm Inc. (Brantford, Ontario, Canada). The sponsor is aware of the content of the submitted material but neither played any role nor exerted any influence in the design of the study, conduct of the research, or reporting of the results.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a simulation study so there are no underlying data. One part of the study was based on data from the Medical Expenditure Panel Survey in the US. Eligible clients can apply for such data through the relevant portal. https://drive.google.com/file/d/1pd2e9qEa6nIMV9UpCPX4mI2SUTaUr9Yw/view?usp=sharing ACTAsthma Control TestFEV1Forced Expiratory VolumeGBDGlobal Burden of DiseaseGINAGlobal Initiative for AsthmaICERIncremental Cost Effectiveness RatioICSInhaled CorticosteroidsLTRALeukotriene receptor antagonist therapyMCTMethacholine Challenge Test (Bronchoprovocation Test)OROdds RatioPC20The concentration of methacholine needed to produce a 20% fall in FEV1QALYQuality Adjusted Life YearUSUnited States ER -